top of page
Strategic Impact in Action
Real examples of how we help biotech and pharma leaders navigate complexity, make better decisions, and unlock value across the product lifecycle.
A mid-sized pharmaceutical company was finalizing development of a product for an orphan indication. While clinical results were promising in this niche setting, the same mechanism of action held potential for a high-unmet-need, broader indication. However, launching into the broader market risked substantial price erosion—potentially compromising profitability in the orphan setting.
A large pharmaceutical company asked us to evaluate the business potential of a new cardiovascular product. Upon review, we discovered a critical misalignment between the clinical development plan and the Target Product Profile (TPP). The TPP aimed to demonstrate superiority over a competitor, while the clinical development plan was designed to establish non-inferiority, risking the commercial viability of the product.
A client planned to pursue staggered regulatory approvals—initially launching with surrogate endpoint data, with outcome data to follow 18 months later. While this accelerated time to market, it risked anchoring the product at a lower price point, which could be difficult to renegotiate upward—even after superior outcomes were confirmed.
bottom of page